Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

BTC study positive In the BTC trial – codenamed KEYNOTE-966 – a combination of Keytruda with chemotherapy ... Discover how AI is transforming the pharma commercial strategy.

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Merck (NYSE:MRK) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. Analysts anticipate a profit of $1.57 per share (-26.3% Y/Y) on revenue of $16.51B (+3.2% Y ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

It is the only treatment other than Keytruda to improve survival in previously ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma ...

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S. drugmaker's ...

Keytruda racked up a stunning $25 billion in sales last year ... Stocks don't get much riskier than Summit Therapeutics. At ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Keytruda is now under threat not only from ... a further potential $1.7 billion in developmental, regulatory and commercial milestone payments. Other issues that affected performance were a ...

Commercial real estate brokers are required to have expertise in market data and financial analysis to best serve clients. They negotiate deals for various property types like office spaces ...

MSD will provide KEYTRUDA for the Exelixis-sponsored Phase ... retaining all worldwide commercial and marketing rights to zanzalintinib. Exelixis product development and medical affairs executive ...